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Abstract
Although regular screening mammography has been suggested to be associated
with improvements in the relative survival of breast cancer in recent years, the
appropriate age to start screening mammography remains controversial. In
November 2009, the United States Preventive Service Task Force published
updated guidelines for breast cancer, which no longer support routine screening
mammography for women aged 40–49 years, but instead, defer the choice of
screening in that age group to the patient and physician. The age to begin
screening differs between guidelines, including those from the Task Force, the
American Cancer Society and the World Health Organization. It remains
unclear how this discrepancy impacts patient survival, especially among certain
subpopulations. Although the biological characteristics of breast cancer and
peak age of incidence differ among different ethnic populations, there have
been few reports that evaluate the starting age for screening mammography
based on ethnicity. Here, we discuss the benefits and harm of screening mammography in the fifth decade, and re-evaluate the starting age for screening
mammography taking ethnicity into account, focusing on the Asian population.
Breast cancer incidence peaked in the fifth decade in Asian women, which has
been thought to be due to a combination of biological and environmental factors. Previous reports suggest that Asian women in their 40s may receive more
benefit and less harm from screening mammography than the age-matched
non-Asian US population. Therefore, starting screening mammography at age
40 may be beneficial for women of Asian ethnicity in well-resourced countries,
such as Japanese women who reside in Japan.

doi: 10.1002/cam4.468

Introduction
Breast cancer is the most common cancer diagnosis, and the
second most common cause of cancer death in US women
[1]. Although incidence remains high (Fig. 1), mortality in
the US has continued to decline since the early 1990s
1136

(Fig. 2) [2–4]. This improved relative survival for breast
cancer has been attributed to the advances in systemic therapy as well as screening mammography. As a result of
increased screening and earlier detection of breast cancer,
the cases of early breast cancer have increased, which has
also been associated with decreased mortality in the US [5].
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it remains unclear how the discrepancy affects patient
survival, especially among certain subpopulations [13].
Breast cancer incidence and mortality differ between
women in the US and Japan (Figs. 1 and 2). Interestingly,
age-specific incidence curves also differ between the two
populations (Fig. 3). Although the biological characteristics of breast cancer differ by ethnicity, there have been
few reports that discuss the starting age of screening
mammography taking ethnicity into account [14, 15].
Here, we discuss the benefits and harm of screening
mammography, and reconsider the starting age for
screening mammography taking ethnicity into account,
focusing on the Asian population.
Figure 1. Trend in breast cancer incidence (2003–2010). Data for the
US were obtained from age-adjusted SEER incidence rates by cancer
site all ages all races female 2000–2011 (SEER) [2]. Data for Japan
were obtained from National Cancer Center Research Institute [17].

Figure 2. Breast cancer mortality age-standardized rate, all ages
(1950–2011). Data were obtained from International Agency for
Research on Cancer (IARC) [3].

Screening mammography has been shown to reduce
breast cancer mortality by randomized controlled clinical
trials (RCTs) [6–8]. In fact, the breast cancer mortality
reducing effect of screening mammography was reported
by the United States Preventive Service Task Force (USPSTF) in 2002 [9, 10]. Although the survival benefits of
screening mammography have been established by RCTs,
the appropriate patient age to start screening remains in
question [11, 12]. In November 2009, the USPSTF published updated breast cancer screening guidelines that differed markedly from their last update in 2002 [6, 7, 13].
The new guidelines no longer support routine screening
mammography for women ages 40–49 years. Instead, they
defer the decision to screen in that age group to the
choice of the patient and physician. [1, 6, 7, 13] The
updated guidelines were different from others, including
the American Cancer Society (ACS) guidelines; however,
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Incidence and Mortality of Breast
Cancer Vary by Ethnicity; Should All
American Women Be Screened the
Same Way?
The incidence and mortality of breast cancer vary across
countries and regions, with four to five-fold differences in
incidence [16]. Incidence and mortality of breast cancer
are in general highest in North America and Europe, and
lowest in Asia [14]. However, as has been previously
pointed out in the journal, Science, not only the incidence but also the mortality of breast cancer in Japan has
been increasing since 1970 (Figs. 1 and 2) [17, 18].
Today, breast cancer is the most common cancer diagnosed in Japanese women, and the fourth most common
cause of cancer death among Japanese women [19].
Increased exposure to risk factors, such as longer exposure to endogenous sex hormones, body mass index
(BMI), and lower physical activity, is thought to affect
the incidence of breast cancer in Japanese women [19].
More importantly, however, it is consensus among Japanese researchers that one of the major reasons for the
increasing mortality is a lower rate of screening
mammography in Japan [20].
The overall screening mammography rate in the US
across all ethnicities is 72.4% [21] and this high-examination rate has resulted in improved breast cancer survival
[5]. In contrast, the screening mammography rate in
Japan is only 24.3% [22]. Accordingly, it is difficult to
evaluate the impact of screening mammography on breast
cancer mortality when the rate of screening mammography is so low in Japan. Japanese researchers believe that
the low rate of screening is partially due to a lack of
appreciation for the importance of cancer screening
within the general Japanese population [20, 23]. Given
the differences in the screening mammography rates and
the time-shift of breast cancer mortality between the US
and Japan, and considering that similar advanced cancer
therapies are available in both countries, it is likely that
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Figure 3. Breast cancer incidence by age group. Data for the US
were obtained from age-Specific (Crude) SEER incidence rates by
cancer site all ages all races female (2007–2011) [2]. Data for Japan
were obtained from National Cancer Center Research Institute (2010)
[17].

screening mammography plays an important role in
explaining these differences in outcomes.
In addition to the differences in breast cancer incidence
and mortality between women in the US and Japan, agespecific incidence curves also differ between the two populations (Fig. 3). Older women have a higher incidence of
breast cancer in the US, while the highest incidence was
within the 45–49 age group in Japan [2, 17]. Because of
this younger peak age in Japanese women, screening
mammography in the 40–49 age group may provide a
greater benefit in Japanese women.

The Mortality Reduction Effect of
Screening Mammography
To examine the effect of screening mammography on
mortality, RCTs have been conducted in the US and Europe in the past several years [8, 24–37]. A meta-analysis
of those RCTs evaluated the efficacy of screening mammography on the basis of the relative risk of breast cancer
mortality [10]. In 2002, the USPSTF reported that the relative risk of breast cancer mortality in the screening
group during a 14-year observation period was 0.84 for
all ages [7, 8, 10]. In other words, breast cancer mortality
was reduced by 16% in the screening group compared
with the unscreened group [7, 8, 10]. Because the US and
many countries in Europe encourage screening mammography as a matter of national public health policy, the
screening rate for breast cancer is high (70–80%) [8].
These approaches have achieved a statistically significant
decrease in breast cancer mortality due to the increased
detection of early-stage disease [8].
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Although the RCTs have established the survival benefits of screening mammography, breast cancer screening
continues to be a topic of discussion [38–42]. It has been
suggested that the benefit of screening mammography has
been overestimated by bias because the reports differ
widely in the context and intensity of screening, as well as
in the interpretation of the available evidence [39, 43].
Furthermore, some argue that the reduction in mortality
might be due to advances in cancer therapies rather than
screening mammography [39]. However, such an argument does not account for the differences in the timeshift of breast cancer mortality between the US and Japan,
where literally identical advanced cancer therapies are
available in both countries. As a matter of fact, the 5-year
relative survival rates of breast cancer patients by stage at
diagnosis in Japan are as high as those in the US
(Table 1) [2, 44]. Nevertheless, breast cancer mortality in
the US has continued to decline since the early 1990s,
while the mortality in Japan has been increasing since
1970. One of the remarkable differences is the overall
screening mammography rate in Japan is approximately
one-third of that in the US, 24.3% versus 72.4%, respectively [21, 22]. Considering the differences in the timeshift of breast cancer mortality and the screening
mammography rates between the US and Japan, screening
mammography is thought to be one of the key factors
that contributes to improved breast cancer mortality.

Issues Regarding Starting Screening
Mammography at age 40
The ACS recommends that average-risk women should
begin annual screening with mammography at the age of
40 years [45]. The ACS guidelines for breast cancer
screening in average-risk women were last updated in
2003 [46], and screening guidelines for women at very
high risk were last updated in 2007 [47, 48]. There is no
specific upper age at which mammography screening
should be discontinued [45]. Rather, the decision to stop
regular mammography screening should be individualized
based on the potential benefits and harm of screening in
the context of overall health status and estimated longevity [49]. As long as a woman is in good health and would
be a candidate for breast cancer treatment, she should
continue to be screened with mammography [45]. However, there is uncertainty as to the balance between the
benefits and harm of screening mammography in women
aged 40 49 years.
Interestingly, the USPSTF reports that the relative risk
of death due to breast cancer for women randomly
assigned to mammography screening was 0.78 for women
aged 50 years or older, and 0.85 for those aged 40–
49 years [7, 8]. This means that breast cancer mortality
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Table 1. Five-year relative survival by stage at diagnosis in the US
and Japan.
5-year relative survival (%)
Stage at diagnosis

USA1

Japan2

Localized
Regional
Distant
All stages

98.5
84.6
25.0
89.2

98.2
84.5
28.2
89.1

1

Data were obtained from SEER 18 2004–2010 [2].
Data were obtained from Monitoring of Cancer Incidence in Japan Survival 2003–2005 [44].

2

was reduced by 22% for women aged 50 years or older,
and by 15% for women aged 40–49 [7, 8, 10]. The conclusions of the USPSTF in 2002 were as follows: “Based
on fair evidence, screening mammography in women aged
40–70 years decreases breast cancer mortality [8]. The
benefit is higher for older women, in part because their
breast cancer risk is higher.”[8–10]
The USPSTF reported their updated guidelines for
screening mammography after a comprehensive assessment of the efficacy of breast cancer screening in terms of
the net benefit, which is the sum of the benefits and harm
of screening mammography [6, 7]. The benefits include a
reduction in the risk of dying with breast cancer, less
aggressive surgery and/or less aggressive adjuvant therapy
and a greater range of treatment options when breast cancer is detected early. The harm of mammography includes
radiation exposure, pain, anxiety, overdiagnosis, false-negative, and false-positive mammography results, and cost
[6]. Screening mammography for women aged 39–
49 years had a 15% mortality reduction based on the
results of eight meta-analysis studies [7, 27, 32, 34–37].
On the other hand, the harm, especially false-positive
mammography, unnecessary additional imaging tests and
histological examinations, were relatively greater in
women aged 40–49 years when comparing the analyzed
data with the data of the Breast Cancer Surveillance Consortium (BCSC) [7]. Thus, the USPSTF recommended
against routine screening mammography in women aged
40–49 years (grade C recommendation) [6]. That recommendation, however, is not free from criticism [50], and
the appropriate age for starting screening mammography
remains controversial.
Most recently, the World Health Organization (WHO)
produced a guideline named “WHO position paper on
mammography screening” [43]. This guideline recommended population-based screening mammography for
women aged 40–49 years only if such a program is conducted in the context of rigorous research and monitoring and evaluation, if the conditions for implementing an
organized program specified in this guideline are met,
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and if shared decision-making strategies are implemented
so that women’s decisions are consistent with their values
and preferences (conditional recommendation based on
moderate quality evidence). On the other hand, WHO
strongly recommends against the implementation of population-based screening programs for women aged
40 49 years in limited resource settings with weak or
relatively strong health systems.

Women Aged 40–49 in Japan May
Have Less Harm from Screening
Mammography than Age-matched
Women in the US
In Japan, screening mammography, which was endorsed
in 2000 for women aged 50 years and over, was expanded
to include women aged 40–49 years in 2004 [51]. Breast
cancer incidence increases in women after menopause in
the US, while the highest incidence was seen in the 45–
49 years age group in Japan (Fig. 3). Therefore, it is
thought that screening mammography in the 40–49 age
group is important in Japan. However, at the time of that
endorsement, data regarding the improvement in survival
and the harm of screening mammography were not yet
available [51]. To address this issue, the harm of the
screening mammography was investigated in Japanese
women [51].
Kasahara et al.[51] studied the harm of screening
mammography using the initial test data collected from
five prefectures in Japan. The analyzed harm included
false-positive results, unnecessary additional imaging tests
and biopsies, which were compared with US data [51].
They collected screening mammography data from
144,848 participants from five Japanese prefectures to
assess harm by age group (Fig. 4) [51]. The rate of cancer
detection in the 40–49 age group was 0.28%. The falsepositive rate (9.6%), rates of additional imaging by mammography (5.8%) and ultrasound (7.3%), fine needle
aspiration cytology (FNA) (1.6%) and biopsy (0.6%) were
higher in the 40–49 age group than in the other age
groups [51].
The BCSC reported that the rate of cancer detection in
the 40–49 age group was 0.26% in the US, which is similar to the data in Japan [51]. The false-positive rate
(9.8%) and rates of additional imaging (8.4%) were comparable to the data in Japan (9.6% and 7.3%, respectively)
[51]. The rate of biopsy was 0.9%, which appears to be
higher than in Japanese reports (0.6%) [51]. Interestingly,
the open surgical biopsy rate in US was 0.32%, while the
rate in Japan was only 0.07% [51].
What makes surgeons in the US decide to perform
more open surgical biopsies? There are several possible
reasons for this difference which may include medical
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Figure 4. Comparison of the estimated number of additional imaging, FNA, biopsy and its procedures, false positives, and detected cancers per
1000 screened women in their 40s between Japan and the US. The data were reported by Kasahara et al. [51].

and social factors. Adepoju et al.[52] reported that factors
associated with higher rates of surgical biopsy include
younger age; Asian ethnicity; private insurance; small,
rural, and non-teaching hospitals. Previous studies have
shown that among women with breast cancer, younger
women are more likely to present with a breast mass, and
it is possible that these women would prefer to have complete excision of the mass. The reason for the higher rates
associated with Asian ethnicity may be multifactorial:
health literacy, socioeconomic status, patient preference,
differential access to care and difference in imaging characteristics.
Interestingly, previous studies showed that reimbursement does impact what surgery is performed for breast
cancer, since surgical biopsy has been shown to be more
expensive than minimally invasive biopsies. Therefore,
incentives by third-party insurance payers may be necessary to lower the rates of surgical biopsy. The increased
rate of surgical biopsy was also associated with small,
rural, and nonteaching hospitals. Other contributing factors include access to appropriate equipment and the limited technical expertise of regional surgeons and imaging
subspecialists. Moreover, another factor includes “defensive medicine” which may incentivize a more aggressive
surgical approach to biopsy out of fear due to the higher
risk of being sued in the US than in Asia. Further studies
examining these factors may be valuable to reveal the
causes of higher surgical biopsy rates, and to increase the
rate of minimally invasive biopsy.
The harm in terms of false positivity and the performance of unnecessary additional imaging did not show
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significant differences between the US and Japan [51].
However, additional biopsies were much less frequent in
Japan than in the US as reported by BCSC in all age
groups [51]. This may be explained by the difference in
attitude towards aggressively pursuing additional open
biopsies among surgeons between Japan and the US.
Taken together, screening mammography appears to be
less harmful in Japan than in the US. Considering that
the highest incidence was seen in the 45–49 age group in
Japan, Japanese women in their 40s appear to receive
more benefit from screening mammography compared to
the same age group in the US.

Why Does Breast Cancer Incidence in
Japanese Women Peak in the Fifth
Decade?
Breast cancer incidence increases in women after menopause in the US, while the highest incidence was seen in
the 45–49 age group in Japan [4]. The difference in peak
age of breast cancer incidence in Japan can be explained
by a combination of environmental and biological factors
that may affect breast cancer incidence (Fig. 5) [14].
There are significant differences in the distribution of risk
factors for postmenopausal breast cancer, particularly the
high prevalence of obesity and use of hormone replacement therapies in the US compared to Japan (Fig. 5) [4,
53, 54]. It has been reported that normal breast tissue is
much less likely to be ER-positive in Japanese women
than in US women [14, 55]. Therefore, it is suggested
that normal breast tissue of Japanese women has less

ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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Figure 5. Proposed environmental risk factors for breast cancer and biological factors for Asian women. The reason why breast cancer incidence
in Japanese women peaks in the fifth decade can be explained by a combination of the environmental and biological factors that may affect
breast cancer incidence.

susceptibility to estrogen [14]. Indeed, there is a significantly lower prevalence of postmenopausal estrogen
receptor (ER)-positive breast cancer in Japanese women
living in Japan compared with Western populations [14].
ER-positive breast cancer is sensitive to epidemiological
risk factors, including parity, age at first partum, and
BMI, while ER-negative cancer is somewhat less sensitive
[14]. Taken together, the combination of environmental
and biological factors appears to impact the differences in
age of peak breast cancer incidence between Japanese and
US women.

Peak Age of Breast Cancer Incidence
in Asian American Women Is Similar
to Japanese Women; Asians Comprise
About 5% of the Overall US
Population
As described above, the highest incidence of breast cancer
occurred in the 45–49 age group in Japan, probably due
to a combination of biological and environmental factors.
What about other Asian populations? Interestingly, many
studies in other Asian countries also observed that agespecific incidence rates peaked at around age 50 and then
declined with age. This trend was observed not only in
Japan, but also in Korea, Taiwan, Hong Kong, and Singapore [14]. It has been reported that ER positivity among
breast cancer patients in Asia was also lower than in Western women [56, 57]. These findings are important to
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consider in the West as well, as there are Asian populations also in the US. According to population demographic statistics, Asian Americans comprise about 5% of
the overall US population [58]. For those women of
Asian ethnicity in the US, we believe that starting screening mammography in the fifth decade may provide a
similar benefit as it has in Japan.

Conclusions
The peak age of breast cancer incidence differs between
US and Asian women. Currently, both environmental and
biological factors are proposed to be the causes for this
difference. Asian women in their 40s appear to receive
more benefit from screening mammography compared to
age-matched non-Asian women in the US. Therefore, we
recommend that screening mammography start at age 40
for women of Asian ethnicity, such as Japanese women
who reside in Japan. Since the effectiveness of routine
screening relies on societal resources, which is the basis of
WHO and USPSTF recommendations against routine
screening in the age 40–49 group, our recommendation
may therefore apply to well-resourced countries. For
example, our results implicate an intriguing possibility
that our recommendation may be applicable for ethnically
Asian women in the US. Although the benefit of
early screening for these women needs to be proven by a
large prospective study, our results suggest that ethnicity
and environment should be taken into account when
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considering screening mammography as a public health
measure.

Conflict of Interest

14.

None decalred.
References
1. Siegel, R., J. Ma, Z. Zou, and A. Jemal. 2014. Cancer
statistics, 2014. CA Cancer J. Clin. 64:9–29.
2. Howlader, N., A. M. Noone, M. Krapcho, et al. eds. SEER
cancer statistics review, 1975–2011. National Cancer
Institute, Bethesda, MD. Available at http://seer.cancer.gov/
csr/1975_2011/, based on November 2013 SEER data
submission, posted to the SEER web site, April 2014.
3. World Health Organization. International Agency for
Research on Cancer (IARC). Available at http://wwwdep.iarc.fr/WHOdb/WHOdb.htm (accessed March 15, 2015).
4. Iwasaki, M., and S. Tsugane. 2011. Risk factors for breast
cancer: epidemiological evidence from Japanese studies.
Cancer Sci. 102:1607–1614.
5. Berry, D. A., K. A. Cronin, S. K. Plevritis, et al. 2005.
Effect of screening and adjuvant therapy on mortality from
breast cancer. N. Engl. J. Med. 353:1784–1792.
6. U.S. Preventive Services Task Force. 2009. Screening for
breast cancer: U.S. Preventive Services Task Force
recommendation statement. Ann. Intern. Med. 151: 716–
726, w-236.
7. Nelson, H. D., K. Tyne, A. Naik, C. Bougatsos, B. K.
Chan, and L. Humphrey. 2009. Screening for breast
cancer: an update for the U.S. Preventive Services Task
Force. Ann. Intern. Med. 151:w237–w742.
8. Morimoto, T., T. Nagao, K. Okazaki, M. Kira, Y.
Nakagawa, and A. Tangoku. 2009. Current status of breast
cancer screening in the world. Breast Cancer 16:2–9.
9. U. S. Preventive Services Task Force. 2002. Screening for
breast cancer recommendations and rationale. Ann. Intern.
Med. 137:344–346.
10. Humphrey, L. L., M. Helfand, B. K. Chan, and S. H.
Woolf. 2002. Breast cancer screening: a summary of the
evidence for the U.S. Preventive Services Task Force. Ann.
Intern. Med. 137:347–360.
11. Printz, C. 2014. Mammogram debate flares up: Latest
breast cancer screening study fuels controversy. Cancer
120:1755–1756.
12. Hellquist, B. N., K. Czene, A. Hjalm, L. Nystrom, and H.
Jonsson. 2015. Effectiveness of population-based service
screening with mammography for women ages 40 to 49
years with a high or low risk of breast cancer:
socioeconomic status, parity, and age at birth of first child.
Cancer 121:251–258.
13. Habtes, I., D. Friedman, C. Raskind-Hood, et al. 2013.
Determining the impact of US mammography screening

1142

15.

16.

17.

18.
19.

20.

21.

22.

23.

24.

25.

26.

guidelines on patient survival in a predominantly African
American population treated in a public hospital during
2008. Cancer 119:481–487.
Leong, S. P., Z. Z. Shen, T. J. Liu, et al. 2010. Is breast
cancer the same disease in Asian and Western countries?
World J. Surg. 34:2308–2324.
Onega, T., E. F. Beaber, B. L. Sprague, et al. 2014. Breast
cancer screening in an era of personalized regimens: a
conceptual model and National Cancer Institute initiative
for risk-based and preference-based approaches at a
population level. Cancer 120:2955–2964.
World Health Organization. GLOBOCAN 2012: Estimated
cancer incidence mortality and prevalence Worldwide in
2012. Available at http://globocan.iarc.fr/Pages/
fact_sheets_cancer.aspx (accessed March 15, 2015).
National Cancer Center Research Institute. Cancer
statistics. Available at http://gdb.ganjoho.jp/graph_db/
gdb1?smTypes=14 (accessed March 15, 2015).
Servick, K. 2014. Breast cancer: a world of differences.
Science 343:1452–1453.
Katanoda, K., T. Matsuda, A. Matsuda, et al. 2013. An
updated report of the trends in cancer incidence and
mortality in Japan. Jpn. J. Clin. Oncol. 43:492–507.
Tsunematsu, M., H. Kawasaki, Y. Masuoka, and M.
Kakehashi. 2013. Factors affecting breast cancer screening
behavior in Japan–assessment using the health belief model
and conjoint analysis. Asian Pac. J. Cancer Prev. 14:6041–
6048.
Centers for Disease Control and Prevention. National
Center for Health Statistics, National Health Interview
Survey, 2010. (Among women aged 50-74 years.).
Available at http://www.ahrq.gov/research/findings/nhqrdr/
nhdr13/chap2.html (accessed March 15, 2015).
Ministry of Health, Labour and Welfare. Comprehensive
Survey of Living Conditions, Japan, 2012 (Women 40
years or older). Available at http://www.mhlw.go.jp/stf/
houdou/2r9852000001igt0.html (accessed March 15,
2015).
Uchida, K., H. Ohashi, S. Kinoshita, et al. 2015. Breast
cancer screening and the changing population pyramid of
Japan. Breast Cancer 22:172–176.
Miller, A. B., C. J. Baines, T. To, and C. Wall. 1992.
Canadian National Breast Screening Study: 1. Breast cancer
detection and death rates among women aged 40 to 49
years. CMAJ 147:1459–1476.
Miller, A. B., C. J. Baines, T. To, and C. Wall. 1992.
Canadian National Breast Screening Study: 2. Breast cancer
detection and death rates among women aged 50 to 59
years. CMAJ 147:1477–1488.
Bjurstam, N., L. Bjorneld, S. W. Duffy, et al. 1997. The
gothenburg breast cancer screening trial: preliminary
results on breast cancer mortality for women aged 39-49.
J. Natl. Cancer Inst. Monogr. 53–55.

ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

J. Tsuchida et al.

27. Tabar, L., G. Fagerberg, H. H. Chen, et al. 1995.
Efficacy of breast cancer screening by age. New results
from the Swedish Two-County Trial. Cancer 75:2507–
2517.
28. Frisell, J., E. Lidbrink, L. Hellstrom, and L. E. Rutqvist.
1997. Followup after 11 years–update of mortality results
in the Stockholm mammographic screening trial. Breast
Cancer Res. Treat. 45:263–270.
29. Alexander, F. E., T. J. Anderson, H. K. Brown, et al. 1999.
14 years of follow-up from the Edinburgh randomised trial
of breast-cancer screening. Lancet 353:1903–1908.
30. Miller, A. B., T. To, C. J. Baines, and C. Wall. 2000.
Canadian National Breast Screening Study-2: 13-year
results of a randomized trial in women aged 50–59 years.
J. Natl. Cancer Inst. 92:1490–1499.
31. Miller, A. B., T. To, C. J. Baines, and C. Wall. The Canadian
National Breast Screening Study: update on breast cancer
mortality. J. Natl. Cancer Inst. Monogr. 1997: 37–41.
32. Miller, A. B., T. To, C. J. Baines, and C. Wall. 2002. The
Canadian National Breast Screening Study-1: breast cancer
mortality after 11 to 16 years of follow-up. A randomized
screening trial of mammography in women age 40 to 49
years. Ann. Intern. Med. 137:305–312.
33. Andersson, I., K. Aspegren, L. Janzon, et al. 1988.
Mammographic screening and mortality from breast
cancer: the Malmo mammographic screening trial. BMJ
297:943–948.
34. Nystr€
om, L., I. Andersson, N. Bjurstam, J. Frisell, B.
Nordenskj€
old, and L. E. Rutqvist. 2002. Long-term effects
of mammography screening: updated overview of the
Swedish randomised trials. Lancet 359:909–919.
35. Habbema, J. D., G. J. van Oortmarssen, D. J. van Putten,
J. T. Lubbe, and P. J. van der Maas. 1986. Age-specific
reduction in breast cancer mortality by screening: an
analysis of the results of the Health Insurance Plan of
Greater New York study. J. Natl. Cancer Inst. 77:317–320.
36. Moss, S. M., H. Cuckle, A. Evans, L. Johns, M. Waller, and
L. Bobrow. 2006. Effect of mammographic screening from
age 40 years on breast cancer mortality at 10 years’ followup: a randomised controlled trial. Lancet 368:2053–2060.
37. Bjurstam, N., L. Bjorneld, J. Warwick, et al. 2003. The
Gothenburg breast screening trial. Cancer 97:2387–2396.
38. Webb, M. L., B. Cady, J. S. Michaelson, et al. 2014. A
failure analysis of invasive breast cancer: most deaths from
disease occur in women not regularly screened. Cancer
120:2839–2846.
39. Berry, D. A. 2014. Failure of researchers, reviewers, editors,
and the media to understand flaws in cancer screening
studies: application to an article in Cancer. Cancer
120:2784–2791.
40. Kopans, D. B., M. L. Webb, and B. Cady. 2014. The 20year effort to reduce access to mammography screening:
historical facts dispute a commentary in Cancer. Cancer
120:2792–2799.

ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Screening Mammography for Asian Women

41. Helvie, M. A., J. T. Chang, R. E. Hendrick, and M.
Banerjee. 2014. Reduction in late-stage breast cancer
incidence in the mammography era: implications
for overdiagnosis of invasive cancer. Cancer
120:2649–2656.
42. Bleyer, A., C. R. Thomas Jr, C. Baines, and A. B. Miller.
2014. Flawed assumptions used to defend screening
mammography. Cancer 121:320–321.
43. World Health Organization. WHO position paper on
mammography screening. Available at http://www.who.int/
cancer/publications/mammography_screening/en/ (accessed
March 15, 2015).
44. National Cancer Center. Center for cancer control and
information services. Monitoring of Cancer incidence in
Japan – survival 2003–2005. Available at URL:http://
ganjoho.jp/data/professional/statistics/odjrh3000000hwsaatt/mcij2003-2005_report.pdf (accessed March 15, 2015).
45. Smith, R. A., V. Cokkinides, D. Brooks, D. Saslow, and O.
W. Brawley. 2010. Cancer screening in the United States,
2010: a review of current American Cancer Society
guidelines and issues in cancer screening. CA Cancer J.
Clin. 60:99–119.
46. Smith, R. A., D. Saslow, K. A. Sawyer, et al. 2003.
American Cancer Society guidelines for breast cancer
screening: update 2003. CA Cancer J. Clin. 53:141–169.
47. Saslow, D., C. Boetes, W. Burke, et al. 2007. American
Cancer Society guidelines for breast screening with MRI as
an adjunct to mammography. CA Cancer J. Clin. 57:75–
89.
48. Smith, R. A., V. Cokkinides, and O. W. Brawley. 2012.
Cancer screening in the United States, 2012: a review of
current American Cancer Society guidelines and current
issues in cancer screening. CA Cancer J. Clin. 62:129–142.
49. Walter, L. C., and K. E. Covinsky. 2001. Cancer screening
in elderly patients: a framework for individualized decision
making. JAMA 285:2750–2756.
50. Hendrick, R. E., and M. A. Helvie. 2011. United States
preventive services task force screening mammography
recommendations: science ignored. AJR Am. J.
Roentgenol. 196:W112–W116.
51. Kasahara, Y., M. Kawai, I. Tsuji, et al. 2013. Harms of
screening mammography for breast cancer in Japanese
women. Breast Cancer 20:310–315.
52. Adepoju, L., W. Qu, V. Kazan, M. Nazzal, M. Williams,
and J. Sferra. 2014. The evaluation of national time trends,
quality of care, and factors affecting the use of minimally
invasive breast biopsy and open biopsy for diagnosis of
breast lesions. Am. J. Surg. 208:382–390.
53. Nagata, C. 1996. Prevalence of hormone replacement
therapy and user’s characteristics a community survey in
Japan. Maturitas 25:201–207.
54. Yoshiike, N. 2002. Twenty-year changes in the prevalence
of overweight in Japanese adults the National Nutrition
Survey 1976–95. Obes. Rev. 3:183–190.

1143

Screening Mammography for Asian Women

55. Js, L. 1999. Low oestrogen receptor alpha expression in
normal breast tissue underlies low breast cancer incidence
in Japan. Lancet 354:1787–1788.
56. Shin, H. R., M. Boniol, C. Joubert, et al. 2010. Secular
trends in breast cancer mortality in five East Asian
populations: Hong Kong, Japan, Korea, Singapore and
Taiwan. Cancer Sci. 101:1241–1246.

1144

J. Tsuchida et al.

57. Lim, S. E., M. Back, E. Quek, P. Iau, T. Putti, and J. E. Wong.
2007. Clinical observations from a breast cancer registry in
Asian women. World J. Surg. 31:1387–1392.
58. U.S. Census Bureau. 2010 Census redistricting data (Public
Law 94-171) summary file, Tables P1 and P2. Available at
https://www.census.gov/rdo/data/2010_census.html
(accessed March 15, 2015).

ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

